Arrowhead Pharmaceuticals, Inc.
ARWR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000879407
In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 501 institutions reported holding it in 13F filings for Q2 2026, worth $9.73B in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Arrowhead Pharmaceuticals, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 282
- +10 vs. Q3 2022
- Shares held
- 73.3M
- +3.16M (+4.5%) vs. Q3 2022
- Total value
- $2.97B
- +$653.7M (+28.2%) vs. Q3 2022
- New holders
- 40
- 97 more added
- Sold out
- 30
- 100 more reduced
6 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARWR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 501 | $9.73B |
| Q1 2026 | 437 | $7.58B |
| Q4 2025 | 401 | $7.70B |
| Q3 2025 | 303 | $3.83B |
| Q2 2025 | 281 | $1.67B |
| Q1 2025 | 264 | $1.34B |
| Q4 2024 | 269 | $1.88B |
| Q3 2024 | 272 | $1.90B |
| Q2 2024 | 272 | $2.54B |
| Q1 2024 | 273 | $2.76B |
| Q4 2023 | 266 | $2.37B |
| Q3 2023 | 257 | $2.01B |
| Q2 2023 | 274 | $2.57B |
| Q1 2023 | 257 | $1.85B |
| Q4 2022 | 282 | $2.97B |
| Q3 2022 | 278 | $2.35B |
| Q2 2022 | 279 | $2.54B |
| Q1 2022 | 307 | $3.19B |
| Q4 2021 | 311 | $4.51B |
| Q3 2021 | 297 | $4.16B |
| Q2 2021 | 314 | $5.54B |
| Q1 2021 | 289 | $4.55B |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Arrowhead Pharmaceuticals, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Evoke Wealth, LLC | 0 | $0 | 0.00% | −2,233−100.0% | Sold out |
| Ancora Advisors, LLC | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −837−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −692−100.0% | Sold out |
| Atlas Capital Advisors LLC | 0 | $0 | 0.00% | −220−100.0% | Sold out |
| Evermay Wealth Management LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Almanack Investment Partners, LLC. | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Smithfield Trust Co | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| GPS Wealth Strategies Group, LLC | 0 | $0 | 0.00% | −41−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Howe & Rusling Inc | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| Western Financial Corporation | – | – | – | – | Not filed |
| ACT Capital Management, LLC | – | – | – | – | Not filed |
| American Portfolios Advisors | – | – | – | – | Not filed |
| Beaumont Financial Partners, LLC | – | – | – | – | Not filed |
| Eaton Vance Management | – | – | – | – | Not filed |
| Wipfli Financial Advisors LLC, | – | – | – | – | Not filed |